Dr. Klopp on IMRT for Gynecologic Cancers

Ann H. Klopp, MD, PhD
Published: Tuesday, May 02, 2017



Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.

Among patients who had standard radiation, almost 10% of them had trouble controlling bowel movements, whereas this occurred in only 2% of the patients who had IMRT. According to Klopp, it was surprising how severe the patient experience was.

The community is learning more about patient-reported outcomes that it is more sensitive to many forms of toxicity than physician-reported toxicity, explains Klopp.
 


Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center discusses intensity-modulated radiation therapy (IMRT) for patients with gynecologic cancers.

Among patients who had standard radiation, almost 10% of them had trouble controlling bowel movements, whereas this occurred in only 2% of the patients who had IMRT. According to Klopp, it was surprising how severe the patient experience was.

The community is learning more about patient-reported outcomes that it is more sensitive to many forms of toxicity than physician-reported toxicity, explains Klopp.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x